Nafarelin dosing & administration
A potent GnRH agonist that initially stimulates then suppresses reproductive hormones, used for treating endometriosis and central precocious puberty with convenient nasal spray delivery.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Intranasal: Sprayed into the nose, where it absorbs through the nasal lining.
Bioavailability Moderate — absorbs through the nasal lining and can partly bypass the gut.
2 documented dose levels — separate regimens, not a titration schedule
400 mcg/day (one 200 mcg spray each nostril, AM and PM)
Frequency
Twice daily
Duration
6 months
FDA-labeled endometriosis dose; start between cycle days 2-4. May increase to 800 mcg/day if amenorrhea is not achieved after 2 months [4].
1600-1800 mcg/day (400 mcg per nostril dosing)
Frequency
Twice daily (up to 3 times)
Duration
Until resumption of puberty is desired
FDA-labeled central precocious puberty dose: 1600 mcg/day standard, increasable to 1800 mcg/day [4].
Timing
Best time to take
Use Nafarelin at the same time each day for optimal results. Consistency in timing helps maintain stable levels and maximize therapeutic benefits. Follow your healthcare provider's specific instructions.
With food?
Nafarelin can generally be used with or without food. If you experience any discomfort, try taking it with a light meal. Follow specific guidance from your healthcare provider.
If stacking
Nafarelin should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting your dose
Increase if
- You've tolerated the current dose for the recommended period without significant side effects
- Therapeutic goals haven't been met at the current dose level
- Your healthcare provider recommends dose escalation based on your response
- Lab work or clinical assessments support a higher dose
Decrease if
- Side effects are bothersome or impacting daily life despite management strategies
- You experience any signs of an adverse reaction
- Lab results indicate the need for dose reduction
- Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- Therapeutic goals being met with minimal side effects
- Stable and consistent response to treatment
- Lab values or clinical markers trending in the right direction
- Good tolerance with manageable or absent side effects
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Storage
Before reconstitution
Store Nafarelin in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
After reconstitution
Once reconstituted, Nafarelin should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation — discard the vial
Sample daily schedule
As prescribed (once daily)
As prescribed by your healthcare provider injection
Site: As directed by healthcare provider—rotate sites if applicable
Maintain a consistent schedule for optimal results with Nafarelin. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Safety
Is it safe?
Side effects
Commonly reported: Hot flashes and night sweats (happen in 90% of users), Mood changes including depression or anxiety, Decreased sexual interest, Vaginal dryness, Headaches, Nasal irritation (if using spray formulation), Breast tenderness, Muscle aches and joint pain, Weight gain or changes in body composition, Nausea and upset stomach, Sleep problems, Emotional sensitivity and mood swings, Allergic reactions (rare), Significant bone density loss with extended use, Severe mood disorders requiring medical attention, Hot flashes (flushes of heat and redness), Night sweats and chills, Vaginal dryness and discomfort, Mood depression or anxiety, Changes in sexual desire, Weight changes, Headaches, Muscle and joint aches, Nasal irritation or sinus problems, Breast tenderness or swelling, Acne, Sleep disturbances, Nausea, Fatigue, Bone pain
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Nafarelin
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Nafarelin should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Published research
What the studies show
Magon N, et al. · 2011
Nafarelin is documented as an effective GnRH agonist for managing endometriosis and precocious puberty, with intranasal delivery providing convenient dosing without daily injections.
Warnock JK, et al. · 1998
Study reveals mood-related side effects in GnRH agonist users including nafarelin, establishing the importance of psychological monitoring during long-term hormone suppression therapy.
Garner C · 1994
Early clinical evidence supports nafarelin's effectiveness for endometriosis pain relief and symptom control, with intranasal administration offering improved convenience and patient compliance.
Pfizer / U.S. FDA · 2017
Endometriosis: 400 mcg/day (one 200 mcg spray per nostril AM and PM) for 6 months, increasable to 800 mcg/day. Central precocious puberty: 1600 mcg/day, increasable to 1800 mcg/day.
Head to head
Nafarelin compared
Want the full picture?
The complete Nafarelin research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.